Rituxan fails Phase III lupus trial
This article was originally published in Scrip
Genentech and Biogen Idec have terminated development of their blockbuster monoclonal antibody Rituxan (rituximab) for the treatment of lupus nephritis after it failed to reduce disease activity in a Phase III trial, LUNAR, investigating it in combination with mycophenolate mofetil (MMF) and corticosteroids.
You may also be interested in...
Somaxon Pharmaceuticals and Procter & Gamble Pharmaceuticals are to co-promote Somaxon's insomnia drug Silenor (low-dose doxepin) in the US.
GlaxoSmithKline has begun the Phase III clinical trials programme for its adjuvanted vaccine candidate (GSK1437173A) against herpes zoster for the prevention of shingles.
The EMA has accepted Optimer Pharmaceuticals' MAA for its narrow-spectrum antibiotic fidaxomicin for the treatment of Clostridium difficile infection (CDI) and for the prevention of recurrences of CDI.